FDA warned website Extra Medication for selling unapproved, misbranded ketamine drugs to U.S. consumers without prescriptions.
What happened
FDA reviewed the website www.extramedication.com on March 2, 2026 and found it offering ketamine drug products marketed as "Calypsol" and "ketanest" for sale to U.S. consumers. The site made medical claims for these products, such as using them to induce anesthesia before surgery and to put patients to sleep for surgery. FDA said these products have no approved applications and were offered without a prescription.
What FDA found
The company sells ketamine drugs that FDA has never approved, and no approved application is in effect for these products.
Sections 301(d) and 505(a) of the FD&C Act (21 U.S.C. 331(d), 355(a))The product labels do not give adequate directions for use, which a layperson would need to use the drugs safely.
Section 502(f)(1) of the FD&C Act (21 U.S.C. 352(f)(1))The company offers prescription drugs without requiring a prescription from a licensed practitioner.
Section 503(b)(1) of the FD&C Act (21 U.S.C. 353(b)(1))By offering these drugs for sale to U.S. consumers, the company causes misbranded drugs to be brought into interstate commerce.
Sections 301(a) and 301(k) of the FD&C Act (21 U.S.C. 331(a), 331(k))
What FDA wants
FDA asks the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers, and to send a written response with the corrective steps taken and supporting documents. The response is due within 15 business days of receiving the letter, sent to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov with reference number MARCS-CMS 725152 in the subject line.
Who should pay attention
- online sellers and telehealth sites offering ketamine products
- clinics and compounding pharmacies that stock or promote ketamine
- consumers and clinicians buying drugs from unfamiliar websites
This is a summary. Read the original letter on fda.gov.